Jim Tananbaum is the Founder and Chief Executive Officer of Foresite Capital, a healthcare and life sciences investment firm focused on building and investing in transformative companies at the intersection of biology, artificial intelligence, and engineering. Since founding Foresite in 2011, he has led investments in and helped create possibly some of the most influential companies advancing the future of healthcare, while assembling the talent, capital, data, and scientific infrastructure needed to accelerate innovation.
Throughout his career, Jim has been driven by a conviction that breakthroughs occur when disciplines converge. Since high school, his two enduring passions have been mathematics and computer science on one hand, and biology and medicine on the other. Long before AI became mainstream, he believed that computation would fundamentally reshape the discovery, development, and delivery of healthcare. Foresite was built around that thesis.
Today, Foresite Capital and Foresite Labs focus on creating and supporting AI-native healthcare companies that leverage advances in machine learning, large scale biological data, and modern engineering to transform therapeutics, diagnostics, and healthcare delivery. Jim was an early investor in companies such as 10x Genomics and Insitro and helped incubate pioneering platforms including Xaira Therapeutics, reflecting his belief that the next generation of healthcare leaders will emerge from the convergence of biology and computation.
Over the past three decades, Jim has partnered with entrepreneurs and scientists behind some of healthcare’s most influential growth companies, including 10x Genomics, Alumis, Amerigroup, Element Biosciences, Insitro, Jazz Pharmaceuticals, Latigo Bio, Xaira and numerous category-defining businesses across biotechnology, healthcare services, and medical technology.
Prior to Foresite, Jim co-founded GelTex Pharmaceuticals while attending Harvard Business School. With less than $80 million of invested capital, GelTex successfully developed and commercialized two approved medicines and was acquired by Genzyme for $1.4 billion. One of those medicines, Renvela, continues to generate substantial global sales decades after its launch.
Jim also co-founded and served as the founding Chief Executive Officer of Theravance, where he raised more than $350 million and helped establish a platform that ultimately produced multiple approved respiratory therapies. Theravance later evolved into Innoviva and Theravance Biopharma, which together achieved a market capitalization exceeding $4 billion.
Earlier in his career, Jim co-founded Prospect Venture Partners and was a Partner at Sierra Ventures, where he established the firm’s healthcare investing practice.
Jim earned a BS and BSEE in Applied Mathematics and Electrical Engineering and Computer Science from Yale University. He received his MD from Harvard Medical School through the Harvard-MIT Health Sciences and Technology Program and earned his MBA from Harvard Business School.
Beyond investing, Jim is passionate about advancing the application of AI to science, accelerating biomedical discovery, and supporting the next generation of entrepreneurs and researchers working to improve human health. His work is guided by a simple belief: that the combination of exceptional people, breakthrough science, and modern computation can meaningfully extend and improve human life.
